Ruthigen Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Ruthigen Inc announces pricing of initial public offering
Ruthigen Inc:Pricing of initial public offering of 2,650,000 units, which reflects increase in originally anticipated number of units, with each unit consisting of one share of common stock and one Series A Warrant.Each Series A Warrant is exercisable for one share of common stock and one Series B Warrant to purchase one share of common stock.All of units are being offered by Ruthigen at initial public offering price of $7.25 per unit.Units will not be certificated and shares of common stock and Series A Warrants may be transferred separately immediately upon issuance.Dawson James Securities, Inc. is acting as sole book-running manager for the underwritten offering.
Latest Developments for Ruthigen Inc
Latest Key Developments in Biotechnology
- Solagran Ltd announces management changes
- Cellceutix Corp announces positive top-line data from phase 2b ABSSSI Trial
- Akers Biosciences Inc announces joint venture to market rapid diagnostic tests in China
- Rich Pharmaceuticals Inc announces submission of IND application to FDA for treatment of acute myelocytic leukemia and myelodysplastic syndrome
- Share this
- Digg this